placebo + peginterferon alfa + ribavirin

This combination refers to the control arm used in clinical trials conducted by Boehringer Ingelheim for the investigational drug deleobuvir (BI 207127). It consists of a placebo administered alongside the historical standard of care (SOC) for chronic hepatitis C genotype 1, which at the time of the trials comprised peginterferon alfa and ribavirin. Peginterferon alfa is a pegylated form of interferon-alpha that acts as a cytokine to induce an antiviral state in host cells by binding to the interferon alpha/beta receptor. Ribavirin is a guanosine nucleoside analog that exerts antiviral effects through multiple mechanisms, including the inhibition of inosine monophosphate dehydrogenase (IMPDH) and interference with viral RNA polymerase. This regimen served as the baseline comparator to evaluate the safety, antiviral activity, and pharmacokinetics of adding deleobuvir to the standard treatment in both treatment-naive and treatment-experienced patients.

Other names

Placebo + SOCPlacebo + standard of carePlacebo + standard of care-Boehringer Ingelheim-chronic hepatitis C